Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMortgage Advice Bureau Regulatory News (MAB1)

Share Price Information for Mortgage Advice Bureau (MAB1)

Share Price is delayed by 15 minutes
Get Live Data
520.00    -33.00 (-5.97%)
Bid:
521.00
Ask:
526.00
Spread: 5.00 (0.96%)
Market Cap: £299.22m
MAB1 Live PriceLast checked at - London Stock Exchange

Intraday Mortgage Advice Bureau Share Chart

Trading Update

25 Jul 2024 07:00

RNS Number : 7494X
Mortgage Advice Bureau (Hldgs) PLC
25 July 2024
 

25 July 2024

Mortgage Advice Bureau (Holdings) plc 

("MAB" or the "Group")

Trading Update 

Mortgage Advice Bureau (Holdings) plc (AIM: MAB1) today issues a trading update for the six months ended 30 June 2024, ahead of publishing interim results on 24 September 2024.

Group revenue for the six months ended 30 June 2024 increased by 5% to £123.5m (H1 2023: £117.5m), despite a difficult market backdrop, with UK Finance forecasting there would be a 5% reduction in gross lending in 2024 to £215 bn (2023 gross lending was £226 bn).

MAB also increased its value of gross mortgage completions by 5% and our market share gains were maintained throughout the five months ended 31 May 2024 (the latest available data period), with MAB's share of new lending increasing to 8.2% versus 8.0% for the equivalent timeframe last year.

The average number of mainstream advisers in the first half fell 3% to 1,898 (H1 2023: 1,966), with our adviser numbers having increased following the period end to 1,944 (2023:1,918). 

As expected, we saw a slight dip in the organic number of advisers in H1. Although forecast interest rate reductions have not yet materialised, we are now starting to see that trend reverse. In addition, new advisers from Appointed Representative ("AR") recruitment have started to come through in a more meaningful way since the period end.

We expect to deliver further growth in the remainder of this year as new ARs are recruited into MAB, and our ARs start growing adviser numbers again after more than 20 months of consolidation that reflected market conditions.

Current Trading and Outlook

The Group is trading in line with expectations, with a modest pick-up in activity expected in the second half.

There is a significant amount of re-financing that has been delayed for several months, pending possible rate reductions in the summer. Whilst the market may no longer expect a rate cut in August, at some stage we expect these borrowers will want to switch to a better mortgage rate, rather than sitting on expensive floating rates. The current market expectation is that the Bank of England will cut rates by c. 0.5% by the end of the year.

2024 was always going to be about stability, following an extremely challenging 2023, with momentum building in the latter part of the year and into 2025. We expect base rate reductions to be the trigger for a recovery in housing transactions and a gradual release of pent-up demand.

Peter Brodnicki, CEO of MAB, commented:

"2024 started well, following a difficult 2023. However, most experts have been proved wrong in terms of the pace and scale of any rate reductions this year, and that has consequently delayed many re-finance transactions in H1 and any sustainable pick up in purchase activity.

"Against this challenging backdrop, I am very pleased with how MAB continues to grow its market share. As we did last year, to ensure we are in the best possible shape when market conditions improve, we have continued to invest in technology to drive lead flow and adviser productivity across the Group. The progress we are making will further increase our resilience in more challenging market conditions, whilst supporting accelerated growth when market conditions normalise.

"We look forward to a downward trend in the base rate, which will lead to a more active refinancing market and a build-up to more normal levels of housing transactions. It is very encouraging to now have a new government so focused on housebuilding and other initiatives that will give our market and MAB a tailwind, added to which we expect to see record years in terms of re-financing in 2025/26.

We therefore expect to see activity pick up in the second half of the year and into 2025, when we anticipate our investment in lead generation and retention will contribute more significantly to our ambitious growth plans."

 

Enquiries:

Mortgage Advice Bureau (Holdings) plc +44 (0)1332 525007

Peter Brodnicki, Chief Executive Officer

Ben Thompson, Deputy Chief Executive Officer

Emilie McCarthy, Chief Financial Officer

Nominated Adviser and Joint Broker +44 (0)20 7260 1000

Deutsche Numis

Daniel Werchola / Giles Rolls

Joint Broker +44 (0) 20 7418 8900

Peel Hunt LLP

Andrew Buchanan

 

Media Enquiries:

investorrelations@mab.org.uk

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTLZLLLZDLZBBE
Date   Source Headline
17th Oct 20187:00 amRNSReplacement: Director/PDMR Shareholding
16th Oct 20187:00 amRNSDirector/PDMR Shareholding
4th Oct 20182:24 pmRNSHolding(s) in Company
4th Oct 20188:11 amRNSHolding(s) in Company
28th Sep 20182:16 pmRNSDirector/PDMR Shareholding
25th Sep 20187:00 amRNSHalf-year Report
14th Sep 20184:43 pmRNSDirector/PDMR Shareholding
14th Sep 20187:00 amRNSChange of Adviser
31st Aug 201811:08 amRNSDirector/PDMR Shareholding
28th Aug 20184:10 pmRNSHolding(s) in Company
14th Aug 20183:13 pmRNSDirector/PDMR Shareholding
2nd Aug 201812:07 pmRNSSecond Price Monitoring Extn
2nd Aug 201812:02 pmRNSPrice Monitoring Extension
31st Jul 20185:05 pmRNSDirector/PDMR Shareholding
26th Jul 20187:00 amRNSPre-close Trading Update
16th Jul 20182:34 pmRNSDirector/PDMR Shareholding
2nd Jul 20186:43 pmRNSHolding(s) in Company
2nd Jul 20186:43 pmRNSHolding(s) in Company
29th Jun 20185:06 pmRNSDirector/PDMR Shareholding
14th Jun 20185:28 pmRNSDirector/PDMR Shareholding
7th Jun 20187:00 amRNSBoard Appointment
31st May 20186:16 pmRNSDirector/PDMR Shareholding
23rd May 20184:08 pmRNSDirector/PDMR Shareholding
17th May 20183:10 pmRNSResult of AGM
17th May 201810:31 amRNSDirector/PDMR Shareholding
16th May 20187:00 amRNSAGM Statement
15th May 20187:00 amRNSDirector/PDMR Shareholding
30th Apr 20184:34 pmRNSDirector/PDMR Shareholding
17th Apr 20182:08 pmRNSPosting of Report and Accounts & Notice of AGM
16th Apr 20183:49 pmRNSDirector/PDMR Shareholding
10th Apr 20186:20 pmRNSGrant of options and Director dealing
6th Apr 20187:00 amRNSDirector/PDMR Shareholding
4th Apr 20187:00 amRNSBoard Appointment
29th Mar 20183:23 pmRNSDirector/PDMR Shareholding
28th Mar 20187:26 amRNSBlock Admission Application
20th Mar 20187:00 amRNSFinal Results for the year ended 31 December 2017
15th Mar 20189:38 amRNSDirector/PDMR Shareholding
28th Feb 20184:00 pmRNSDirector/PDMR Shareholding
15th Feb 20188:07 amRNSDirector/PDMR Shareholding
31st Jan 20186:15 pmRNSDirector/PDMR Shareholding
22nd Jan 20187:00 amRNSPre-close Trading Update
15th Jan 20183:31 pmRNSDirector/PDMR Shareholding
8th Jan 20188:56 amRNSNon-Executive Director Board changes
28th Dec 20177:00 amRNSDirector/PDMR Shareholding
14th Dec 20175:59 pmRNSDirector/PDMR Shareholding
30th Nov 20174:23 pmRNSDirector/PDMR Shareholding
14th Nov 20174:31 pmRNSDirector/PDMR Shareholding
13th Nov 201711:21 amRNSHolding(s) in Company
31st Oct 20176:24 pmRNSDirector/PDMR Shareholding
16th Oct 20174:29 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.